Nat Commun:侵袭性前列腺癌中的内含子保留和剪接体研究

2020-05-14 AlexYang MedSci原创

mRNA可变剪接(AS)的异常调控在实体瘤发展和进展中的作用仍旧不确定。

mRNA可变剪接(AS)的异常调控在实体瘤发展和进展中的作用仍旧不确定。

最近,有研究人员首次综合性的描述了人类前列腺癌(PCa)进化过程中的AS情况。研究人员发现,剪接异常调控的严重度与疾病进展有关,并提出内含子保留是PCa干细胞华和侵袭性的一个标志。对274个剪接调控基因(SRGs)的系统性调查发现了普遍存在的基因组拷贝数变异(CNVs),导致了PCa发展和恶化过程中大约68%的SRG基因异常表达。因此,许多SRGs是具有预后性质的。令人惊讶的是,雄激素受体能够控制剪接过程,且与其转录调控不同。在异种种植模型和原生PCa模型中,剪接体调控因子E7107能够逆转癌症恶化并抑制趋势抵抗性PCa(CRPC)。

最后,研究人员指出,他们的结果建立了由SRGs异常调控引起的异常AS情况,并且是PCa侵袭性的一个标志,剪接体可作为CRPC的治疗靶标。

原始出处:

Cheng Liu, Li Liu, Kun Wang et al. VHL-HIF-2α axis-induced SMYD3 upregulation drives renal cell carcinoma progression via direct trans-activation of EGFR. Oncogene. 14 April 2020

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1755361, encodeId=f7451e553611b, content=<a href='/topic/show?id=7a7232e6217' target=_blank style='color:#2F92EE;'>#剪接体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32762, encryptionId=7a7232e6217, topicName=剪接体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=00cd36877321, createdName=diushouji, createdTime=Thu Mar 04 06:46:36 CST 2021, time=2021-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087690, encodeId=2d29208e6904b, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sat Sep 19 07:46:36 CST 2020, time=2020-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884318, encodeId=5070188431873, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Sep 08 16:46:36 CST 2020, time=2020-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022524, encodeId=f6f3202252428, content=<a href='/topic/show?id=21d93036574' target=_blank style='color:#2F92EE;'>#内含子保留#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30365, encryptionId=21d93036574, topicName=内含子保留)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Thu Mar 18 09:46:36 CST 2021, time=2021-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366366, encodeId=36d413663667c, content=<a href='/topic/show?id=186126998e2' target=_blank style='color:#2F92EE;'>#侵袭性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26998, encryptionId=186126998e2, topicName=侵袭性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Sat May 16 13:46:36 CST 2020, time=2020-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382833, encodeId=865b3828333d, content=非常好的文献, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43a21971117, createdName=njwbhuang, createdTime=Fri May 15 06:57:55 CST 2020, time=2020-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040742, encodeId=fde91040e42fb, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri May 15 01:46:36 CST 2020, time=2020-05-15, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1755361, encodeId=f7451e553611b, content=<a href='/topic/show?id=7a7232e6217' target=_blank style='color:#2F92EE;'>#剪接体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32762, encryptionId=7a7232e6217, topicName=剪接体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=00cd36877321, createdName=diushouji, createdTime=Thu Mar 04 06:46:36 CST 2021, time=2021-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087690, encodeId=2d29208e6904b, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sat Sep 19 07:46:36 CST 2020, time=2020-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884318, encodeId=5070188431873, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Sep 08 16:46:36 CST 2020, time=2020-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022524, encodeId=f6f3202252428, content=<a href='/topic/show?id=21d93036574' target=_blank style='color:#2F92EE;'>#内含子保留#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30365, encryptionId=21d93036574, topicName=内含子保留)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Thu Mar 18 09:46:36 CST 2021, time=2021-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366366, encodeId=36d413663667c, content=<a href='/topic/show?id=186126998e2' target=_blank style='color:#2F92EE;'>#侵袭性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26998, encryptionId=186126998e2, topicName=侵袭性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Sat May 16 13:46:36 CST 2020, time=2020-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382833, encodeId=865b3828333d, content=非常好的文献, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43a21971117, createdName=njwbhuang, createdTime=Fri May 15 06:57:55 CST 2020, time=2020-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040742, encodeId=fde91040e42fb, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri May 15 01:46:36 CST 2020, time=2020-05-15, status=1, ipAttribution=)]
    2020-09-19 liuli5079
  3. [GetPortalCommentsPageByObjectIdResponse(id=1755361, encodeId=f7451e553611b, content=<a href='/topic/show?id=7a7232e6217' target=_blank style='color:#2F92EE;'>#剪接体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32762, encryptionId=7a7232e6217, topicName=剪接体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=00cd36877321, createdName=diushouji, createdTime=Thu Mar 04 06:46:36 CST 2021, time=2021-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087690, encodeId=2d29208e6904b, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sat Sep 19 07:46:36 CST 2020, time=2020-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884318, encodeId=5070188431873, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Sep 08 16:46:36 CST 2020, time=2020-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022524, encodeId=f6f3202252428, content=<a href='/topic/show?id=21d93036574' target=_blank style='color:#2F92EE;'>#内含子保留#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30365, encryptionId=21d93036574, topicName=内含子保留)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Thu Mar 18 09:46:36 CST 2021, time=2021-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366366, encodeId=36d413663667c, content=<a href='/topic/show?id=186126998e2' target=_blank style='color:#2F92EE;'>#侵袭性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26998, encryptionId=186126998e2, topicName=侵袭性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Sat May 16 13:46:36 CST 2020, time=2020-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382833, encodeId=865b3828333d, content=非常好的文献, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43a21971117, createdName=njwbhuang, createdTime=Fri May 15 06:57:55 CST 2020, time=2020-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040742, encodeId=fde91040e42fb, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri May 15 01:46:36 CST 2020, time=2020-05-15, status=1, ipAttribution=)]
    2020-09-08 liye789132251
  4. [GetPortalCommentsPageByObjectIdResponse(id=1755361, encodeId=f7451e553611b, content=<a href='/topic/show?id=7a7232e6217' target=_blank style='color:#2F92EE;'>#剪接体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32762, encryptionId=7a7232e6217, topicName=剪接体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=00cd36877321, createdName=diushouji, createdTime=Thu Mar 04 06:46:36 CST 2021, time=2021-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087690, encodeId=2d29208e6904b, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sat Sep 19 07:46:36 CST 2020, time=2020-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884318, encodeId=5070188431873, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Sep 08 16:46:36 CST 2020, time=2020-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022524, encodeId=f6f3202252428, content=<a href='/topic/show?id=21d93036574' target=_blank style='color:#2F92EE;'>#内含子保留#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30365, encryptionId=21d93036574, topicName=内含子保留)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Thu Mar 18 09:46:36 CST 2021, time=2021-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366366, encodeId=36d413663667c, content=<a href='/topic/show?id=186126998e2' target=_blank style='color:#2F92EE;'>#侵袭性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26998, encryptionId=186126998e2, topicName=侵袭性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Sat May 16 13:46:36 CST 2020, time=2020-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382833, encodeId=865b3828333d, content=非常好的文献, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43a21971117, createdName=njwbhuang, createdTime=Fri May 15 06:57:55 CST 2020, time=2020-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040742, encodeId=fde91040e42fb, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri May 15 01:46:36 CST 2020, time=2020-05-15, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1755361, encodeId=f7451e553611b, content=<a href='/topic/show?id=7a7232e6217' target=_blank style='color:#2F92EE;'>#剪接体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32762, encryptionId=7a7232e6217, topicName=剪接体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=00cd36877321, createdName=diushouji, createdTime=Thu Mar 04 06:46:36 CST 2021, time=2021-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087690, encodeId=2d29208e6904b, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sat Sep 19 07:46:36 CST 2020, time=2020-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884318, encodeId=5070188431873, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Sep 08 16:46:36 CST 2020, time=2020-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022524, encodeId=f6f3202252428, content=<a href='/topic/show?id=21d93036574' target=_blank style='color:#2F92EE;'>#内含子保留#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30365, encryptionId=21d93036574, topicName=内含子保留)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Thu Mar 18 09:46:36 CST 2021, time=2021-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366366, encodeId=36d413663667c, content=<a href='/topic/show?id=186126998e2' target=_blank style='color:#2F92EE;'>#侵袭性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26998, encryptionId=186126998e2, topicName=侵袭性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Sat May 16 13:46:36 CST 2020, time=2020-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382833, encodeId=865b3828333d, content=非常好的文献, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43a21971117, createdName=njwbhuang, createdTime=Fri May 15 06:57:55 CST 2020, time=2020-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040742, encodeId=fde91040e42fb, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri May 15 01:46:36 CST 2020, time=2020-05-15, status=1, ipAttribution=)]
    2020-05-16 sunyl07
  6. [GetPortalCommentsPageByObjectIdResponse(id=1755361, encodeId=f7451e553611b, content=<a href='/topic/show?id=7a7232e6217' target=_blank style='color:#2F92EE;'>#剪接体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32762, encryptionId=7a7232e6217, topicName=剪接体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=00cd36877321, createdName=diushouji, createdTime=Thu Mar 04 06:46:36 CST 2021, time=2021-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087690, encodeId=2d29208e6904b, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sat Sep 19 07:46:36 CST 2020, time=2020-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884318, encodeId=5070188431873, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Sep 08 16:46:36 CST 2020, time=2020-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022524, encodeId=f6f3202252428, content=<a href='/topic/show?id=21d93036574' target=_blank style='color:#2F92EE;'>#内含子保留#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30365, encryptionId=21d93036574, topicName=内含子保留)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Thu Mar 18 09:46:36 CST 2021, time=2021-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366366, encodeId=36d413663667c, content=<a href='/topic/show?id=186126998e2' target=_blank style='color:#2F92EE;'>#侵袭性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26998, encryptionId=186126998e2, topicName=侵袭性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Sat May 16 13:46:36 CST 2020, time=2020-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382833, encodeId=865b3828333d, content=非常好的文献, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43a21971117, createdName=njwbhuang, createdTime=Fri May 15 06:57:55 CST 2020, time=2020-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040742, encodeId=fde91040e42fb, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri May 15 01:46:36 CST 2020, time=2020-05-15, status=1, ipAttribution=)]
    2020-05-15 njwbhuang

    非常好的文献

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1755361, encodeId=f7451e553611b, content=<a href='/topic/show?id=7a7232e6217' target=_blank style='color:#2F92EE;'>#剪接体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32762, encryptionId=7a7232e6217, topicName=剪接体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=00cd36877321, createdName=diushouji, createdTime=Thu Mar 04 06:46:36 CST 2021, time=2021-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087690, encodeId=2d29208e6904b, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sat Sep 19 07:46:36 CST 2020, time=2020-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884318, encodeId=5070188431873, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Sep 08 16:46:36 CST 2020, time=2020-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022524, encodeId=f6f3202252428, content=<a href='/topic/show?id=21d93036574' target=_blank style='color:#2F92EE;'>#内含子保留#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30365, encryptionId=21d93036574, topicName=内含子保留)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Thu Mar 18 09:46:36 CST 2021, time=2021-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366366, encodeId=36d413663667c, content=<a href='/topic/show?id=186126998e2' target=_blank style='color:#2F92EE;'>#侵袭性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26998, encryptionId=186126998e2, topicName=侵袭性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Sat May 16 13:46:36 CST 2020, time=2020-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382833, encodeId=865b3828333d, content=非常好的文献, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43a21971117, createdName=njwbhuang, createdTime=Fri May 15 06:57:55 CST 2020, time=2020-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040742, encodeId=fde91040e42fb, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri May 15 01:46:36 CST 2020, time=2020-05-15, status=1, ipAttribution=)]
    2020-05-15 misszhang

    前列腺癌相关研究,学习了,谢谢梅斯

    0

相关资讯

Cancer Res:IRF8与AR负反馈调节回路的缺失能够促进前列腺生长和恩杂鲁胺抗性

在不可治愈的去势抵抗性前列腺癌(CPRC)中,对新的雄激素受体(AR)拮抗剂恩杂鲁胺(ENZ)的抗性是有AR的过表达驱使的。

Clin Cancer Res:基因组不稳定性是侵袭性前列腺癌的区别性特征

侵袭性变体前列腺癌(AVPC)代表着一种临床亚型,可以通过治疗抗性和不良预后区分,并且与肿瘤抑制基因(TSG)PETN、RB1和TP53丧失有关。循环肿瘤细胞(CTC)为AVPC的最小侵入性鉴定和分子

Eur Urol:前列腺癌中的标准化和简化机器人辅助超扩展盆腔淋巴结清扫术

在经历根治性前列腺切除术(RP)的中等风险和高风险前列腺癌(PCa)患者中,扩展盆腔淋巴结清扫术(ePLND)仍旧是淋巴结分期最准确的方法。而在非常高风险PCa患者中可以考虑使用超扩展盆腔淋巴结清扫术

Zydus Cadila推出恩杂鲁胺液体胶囊Obnyx,将使该前列腺癌疗法的价格降低2/3

Obnyx的推出可将治疗费用显着降低近70%,其每周治疗费用为5995卢比,每月治疗费用低于27000卢比。

Eur Urol:恩杂鲁胺雄激素阻断治疗联用对转移激素敏感性前列腺癌患者健康相关生活质量影响研究

ARCHES研究中的转移激素敏感性前列腺癌(mHSPC)中,与单独的ADT治疗相比,恩杂鲁胺与雄激素阻断治疗(ADT)联用能够改善影像学无进展生存(rPFS)。最近,有研究人员评估了长达73周的患者报

Prostate Cancer P D:YAP1的表达在高等级前列腺癌中增加而在神经内分泌前列腺癌中减少

在进行长期的雄激素阻断治疗后,25%到30%的前列腺癌(PCa)会恶化成为侵袭性神经内分泌(NE)表型。YAP1是Hippo途径的一个转录共激活子,其异常的调控已经表明与癌症的恶化有关。然而,其在神经